224 related articles for article (PubMed ID: 14579673)
1. [Theoretical background of angiotensin II receptor blockade and its features in clinical pharmacology].
Winkler G; Jermendy G; Matos L
Orv Hetil; 2003 Sep; 144(36):1763-8. PubMed ID: 14579673
[TBL] [Abstract][Full Text] [Related]
2. Angiotensin II type 1 receptor blockers.
Burnier M
Circulation; 2001 Feb; 103(6):904-12. PubMed ID: 11171802
[No Abstract] [Full Text] [Related]
3. Expanded role for ARBs in cardiovascular and renal disease? Recent observations have far-reaching implications.
Ramahi TM
Postgrad Med; 2001 Apr; 109(4):115-22; quiz 9. PubMed ID: 11317462
[TBL] [Abstract][Full Text] [Related]
4. Angiotensin-II receptor antagonists: their place in therapy.
Kirk JK
Am Fam Physician; 1999 Jun; 59(11):3140-8. PubMed ID: 10392595
[TBL] [Abstract][Full Text] [Related]
5. [Candesartan - a novel AT(1)-angiotensin receptor blocker: peculiarities of pharmacology and experience of use in arterial hypertension].
Sidorenko BA; Preobrazhenskiĭ DV; Soplevenko AV; Ivanova NA; Stetsenko TM
Kardiologiia; 2004; 44(1):55-65. PubMed ID: 15029149
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II receptor blockers: equal or preferred substitutes for ACE inhibitors?
Grossman E; Messerli FH; Neutel JM
Arch Intern Med; 2000 Jul; 160(13):1905-11. PubMed ID: 10888965
[No Abstract] [Full Text] [Related]
7. Comparative angiotensin II receptor blockade in healthy volunteers: the importance of dosing.
Maillard MP; Würzner G; Nussberger J; Centeno C; Burnier M; Brunner HR
Clin Pharmacol Ther; 2002 Jan; 71(1):68-76. PubMed ID: 11823759
[TBL] [Abstract][Full Text] [Related]
8. The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs.
Bauer JH; Reams GP
Arch Intern Med; 1995 Jul; 155(13):1361-8. PubMed ID: 7794084
[TBL] [Abstract][Full Text] [Related]
9. Effects of antihypertensive treatment with angiotensin II receptor blockers on lipid profile: an open multi-drug comparison trial.
Kyvelou SM; Vyssoulis GP; Karpanou EA; Adamopoulos DN; Zervoudaki AI; Pietri PG; Stefanadis CI
Hellenic J Cardiol; 2006; 47(1):21-8. PubMed ID: 16532712
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade.
Ohlstein EH; Brooks DP; Feuerstein GZ; Ruffolo RR
Pharmacology; 1997 Nov; 55(5):244-51. PubMed ID: 9399334
[TBL] [Abstract][Full Text] [Related]
11. [Diurnal blood pressure control in the optimal treatment of hypertension].
Alföldi S
Orv Hetil; 2003 May; 144(18 Suppl 1):895-7. PubMed ID: 12785233
[TBL] [Abstract][Full Text] [Related]
12. [Irbesartan: a new possibility in the treatment of hypertension].
Rapi J
Orv Hetil; 2002 May; 143(21):1187-92. PubMed ID: 12073539
[TBL] [Abstract][Full Text] [Related]
13. [Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
Coca A; Giner V
Rev Esp Cardiol; 1999; 52 Suppl 3():53-8. PubMed ID: 10614150
[TBL] [Abstract][Full Text] [Related]
14. Differential inhibition of the prejunctional actions of angiotensin II in rat atria by valsartan, irbesartan, eprosartan, and losartan.
Shetty SS; DelGrande D
J Pharmacol Exp Ther; 2000 Jul; 294(1):179-86. PubMed ID: 10871310
[TBL] [Abstract][Full Text] [Related]
15. [Role of the renin-angiotensin system on the sympathetic response induced by the cold pressor test in humans].
Zavala LE; Cierco M; Gutiérrez A; Garrido MR; Israel A
Invest Clin; 2007 Jun; 48(2):155-65. PubMed ID: 17598639
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-pharmacodynamic profile of angiotensin II receptor antagonists.
Csajka C; Buclin T; Brunner HR; Biollaz J
Clin Pharmacokinet; 1997 Jan; 32(1):1-29. PubMed ID: 9012554
[TBL] [Abstract][Full Text] [Related]
17. Angiotensin II AT1 receptor antagonists. Clinical implications of active metabolites.
Schmidt B; Schieffer B
J Med Chem; 2003 Jun; 46(12):2261-70. PubMed ID: 12773029
[No Abstract] [Full Text] [Related]
18. Human pharmacokinetic/pharmacodynamic profile of irbesartan: a new potent angiotensin II receptor antagonist.
Ruilope L
J Hypertens Suppl; 1997 Dec; 15(7):S15-20. PubMed ID: 9532516
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II receptor antagonists. Potential in elderly patients with cardiovascular disease.
Burrell LM; Johnston CI
Drugs Aging; 1997 Jun; 10(6):421-34. PubMed ID: 9205848
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin II receptor blockade in normotensive subjects: A direct comparison of three AT1 receptor antagonists.
Mazzolai L; Maillard M; Rossat J; Nussberger J; Brunner HR; Burnier M
Hypertension; 1999 Mar; 33(3):850-5. PubMed ID: 10082498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
